Investing.com - U.S. pharmaceutical giant EIi Lilly reported better-than-expected third quarter earnings and revenue ahead of Wednesday’s opening bell.
Earlier in the day, in its third quarter earnings report, Eli Lilly said adjusted earnings per share came in at USD1.11, beating expectations for USD1.04 per share.
The firm’s third quarter revenue totaled USD5.77 billion, above estimates for revenue of USD5.76 billion.
The pharmaceutical company reaffirmed its 2013 revenue forecast and said it expected full-year earnings per share in a range between USD4.10 to USD4.15, in line with expectations for USD4.14 per share.
Meanwhile, the outlook for U.S. equity markets was lower. The Dow Jones Industrial Average futures indicated a loss of 0.45% at the open, S&P 500 futures pointed to a decline of 0.55%, while Nasdaq 100 futures shed 0.6%.
Earlier in the day, in its third quarter earnings report, Eli Lilly said adjusted earnings per share came in at USD1.11, beating expectations for USD1.04 per share.
The firm’s third quarter revenue totaled USD5.77 billion, above estimates for revenue of USD5.76 billion.
The pharmaceutical company reaffirmed its 2013 revenue forecast and said it expected full-year earnings per share in a range between USD4.10 to USD4.15, in line with expectations for USD4.14 per share.
Meanwhile, the outlook for U.S. equity markets was lower. The Dow Jones Industrial Average futures indicated a loss of 0.45% at the open, S&P 500 futures pointed to a decline of 0.55%, while Nasdaq 100 futures shed 0.6%.